Genetic and Genomic Considerations in Pharmacotherapeutics Vocabulary

Pharmacogenomic Overview and Regulatory Directives

Genetic variants between individuals allow prescribers to select more appropriate, tailored medications for patients. The United States Food and Drug Administration (FDA) lists adverse drug reactions (ADRs) as the fourth leading cause of death in the United States, noting more than $100{,}000$ deaths and $2\,\text{million}$ serious adverse drug events each year. As a result of these significant safety concerns, the FDA has included pharmacogenomic biomarkers in the drug package inserts of more than $250$ medications (Section 12.5 Pharmacogenomics).

Genetic testing is now routinely performed for several pharmacological agents. The FDA strictly requires genetic testing prior to the clinical administration of specific drugs, including maraviroc (Selzentry) and trastuzumab (Herceptin). For other medications, such as warfarin (Coumadin) and carbamazepine (Tegretol), genetic testing is officially recommended by the FDA, though not mandatory.

Professional Competencies and Institutional Educational Frameworks

Key organizations across healthcare have voiced an urgent need for expanded education in genomics and pharmacogenomics to enhance clinical management and patient outcomes. In their 2015 publication, Improving Genetics Education in Graduate and Continuing Health Professional Education, the National Academy of Medicine (NAM)—formerly known as the Institute of Medicine (IOM)—stated that genomics education must be provided for all health professionals. Healthcare providers are expected to master knowledge and competencies in patient education, genetic test ordering and interpretation, and the clinical management of appropriate drug therapies.

In September 2011, the American Nurses Association (ANA) published Essential Genetic and Genomic Competencies for Nurses with Graduate Degrees. This document detailed $38$ specific graduate-level competencies encompassing risk assessment and interpretation, genetic education, clinical management, as well as ethical, legal, and social implications (ELSI). Additional prominent proponents for genomic education and practice integration include the National Institute of Nursing Research (NINR) and the American Association of Physician Assistants (AAPA). A major specialized interest group affiliated with the AAPA is the Society of PAs in Genetics and Genomics (SPAGG).

Several key institutional resources provide guidance on incorporating pharmacogenomics into clinical practice. The Clinical Pharmacogenetics Implementation Consortium (CPIC) offers evidence-based guidelines to assist providers in optimizing drug therapy using genetic testing, accessible at https://cpicpgx.org. The FDA provides the Table of Pharmacogenomic Biomarkers in Drug Labeling and the Table of Pharmacogenetic Associations. The Personalized Medicine Coalition supplies informational tables linking drugs, biomarkers, and indications at http://www.personalizedmedicinecoalition.org/Education/Therapies. Additionally, the Pharmacogenomics Knowledgebase (PharmGKB) serves as a primary repository containing listings of drugs with FDA-approved and Health Canada-approved genetic information on their labels, accessible at https://www.pharmgkb.org.

Comparative Definitions: Genetics, Genomics, and Biomarkers

Following the completion of human genome sequencing in $2003$, patients have benefited from rapid advances in genomic science and technology. Distinguishing between genetics and genomics is fundamental to understanding drug responses. Genetics refers to the study of inheritance, dating back to Gregor Mendel and his pea pod experiments in the 1800s. It focuses on how specific genetic traits are passed from one generation to another through human genes, as well as the physiological effects of individual genes through the production of specific proteins.

Genomics, as defined by the National Human Genome Research Institute, encompasses all of a person's genes (the genome), along with the complex interactions among those genes and between the genome and the environment. Genomic science frequently investigates multifactorial diseases such as asthma, heart disease, and cancer, which arise from intricate interactions between an individual's genome and personal lifestyle or environmental exposures. Human genomics encompasses diverse subfields, including epigenomics, proteomics, microbiomics, and pharmacogenomics. Environmental and lifestyle factors—such as geographic location, dietary habits, sleep duration, work duration, and occupational environment—explain why individuals sharing identical genes can exhibit variable disease expression or different clinical phenotypes.

Pharmacogenomics is defined by the National Institutes of Health (NIH) as the study of how genes affect a person's response to drugs. By combining genomics and pharmacology, pharmacogenomics aims to provide individualized, targeted, and safe drug therapies. Pharmacogenomics is a specialized component of precision medicine. While the terms precision medicine and personalized medicine are frequently used interchangeably, precision medicine denotes a broader, structured approach to identifying effective treatment strategies for specific cohorts of patients who share defined genetic, lifestyle, and environmental factors. The term personalized medicine has generally fallen out of favor because, while providers treat patients individually, scientific research does not develop unique, novel drug products for every distinct individual on the planet.

In pharmacogenomics, gene characteristics evaluated to predict drug responses are designated as biomarkers. Technically defined, a biomarker is a measurable substance whose presence in an organism indicates a specific biological phenomenon or state. Biomarkers inform practitioners of underlying genetic variations and are utilized both to diagnose disease processes and to predict individual reactions to specific pharmacological treatments.

Pharmacogenomic Mechanisms: Genetic Variants Altering Drug Metabolism

The most common mechanism by which genetic variants modify drug responses is the alteration of enzymatic drug metabolism. Gene-based structural variations can either accelerate or decelerate drug breakdown, typically resulting in either a loss of therapeutic efficacy or an escalation of drug toxicity. For drugs with a high therapeutic index (TI), altered metabolic rates generally exert minimal clinical impact. Conversely, for drugs with a low or narrow TI, small increases in circulating drug concentrations can trigger severe toxicity, while small decreases can cause complete therapeutic failure.

Variants in the gene coding for cytochrome P450 2D6 ($\text{CYP2D6}$) markedly reduce the therapeutic benefit of tamoxifen (Soltamox), an agent prescribed to prevent breast cancer recurrence. Tamoxifen is a prodrug that requires metabolic conversion by $\text{CYP2D6}$ into its active metabolite, endoxifen. Women carrying inherited $\text{CYP2D6}$ deficiencies cannot adequately activate tamoxifen and derive minimal therapeutic benefit; clinical data show that poor metabolizers experience a cancer recurrence rate $9.5\,\text{times}$ higher than extensive (good) metabolizers. These non-functional gene variants occur in $8\%$ to $10\%$ of women of European ancestry and up to $40\%$ of individuals of Asian descent. Currently, the FDA neither requires nor explicitly recommends $\text{CYP2D6}$ testing prior to tamoxifen use, although commercial test kits are available.

Variants in the gene encoding cytochrome P450 2C19 ($\text{CYP2C19}$) significantly compromise the efficacy of clopidogrel (Plavix), an antiplatelet drug used to prevent platelet aggregation. Clopidogrel is a prodrug that requires activation by the $\text{CYP2C19}$ enzyme. Approximately $25\%$ of patients express the variant allele $\text{CYP2C19*2}$, producing an enzyme with diminished metabolic capacity. Consequently, these individuals mount a weak antiplatelet response, placing them at heightened risk for stroke, myocardial infarction, and adverse cardiovascular events. Alternative antiplatelet therapies are recommended for patients harboring this variant, and FDA genetic testing is recommended.

Genetic variations in the gene encoding N-acetyltransferase-2 ($\text{NAT2}$) alter the metabolism of isoniazid, a primary antitubercular agent. Among Americans of European heritage, approximately $52\%$ are slow metabolizers and $48\%$ are rapid metabolizers due to distinct enzymatic isoforms. Standard isoniazid dosing without metabolic adjustment leads to treatment failure in rapid metabolizers due to rapid clearance, or drug-induced toxicity in slow metabolizers due to drug accumulation.

Codeine conversion represents another metabolic pathway governed by $\text{CYP2D6}$. Approximately $1\,\text{in}\,14$ individuals ($\approx 7.14\%$) of European heritage possesses a non-functional $\text{CYP2D6}$ variant incapable of converting codeine into its active analgesic form, morphine. As a result, codeine fails to provide pain relief in these patients.

Genetic variants can also substantially increase drug toxicity. Warfarin (Coumadin) is a narrow TI anticoagulant that is inactivated by cytochrome P450 2C9 ($\text{CYP2C9}$). Patients carrying variant alleles such as $\text{CYP2C9*2}$ or $\text{CYP2C9*3}$ (occurring in Caucasian allele frequencies of approximately $11\%$ and $7\%$, respectively, with other alleles like $\text{CYP2C9*5}$, $\text{CYP2C9*6}$, $\text{CYP2C9*9}$, and $\text{CYP2C9*11}$ present in African or Caucasian ancestries) metabolize S-warfarin slowly. S-warfarin is normally converted to 7-hydroxywarfarin by $\text{CYP2C9}$. Slow metabolism causes drug accumulation and severe bleeding. The FDA recommends genetic testing for $\text{CYP2C9}$, although clinical studies note that outcomes using expensive genetic testing are no better than outcomes using traditional, inexpensive coagulation testing (such as INR) that directly measures warfarin's anticoagulant effect.

Thiopurine methyltransferase ($\text{TPMT}$) variants decrease enzymatic inactivation of thiopurine anticancer drugs, including thioguanine (generic) and mercaptopurine (Purinethol). Patients with inherited $\text{TPMT}$ deficiency receiving standard thiopurine dosages accumulate high levels of active drug metabolites, risking severe and potentially fatal bone marrow toxicity (myelosuppression). The FDA recommends pre-treatment $\text{TPMT}$ testing, and identified deficient patients must receive reduced drug dosages.

In the United States, approximately $1\%$ of the population produces a variant form of dihydropyridine dehydrogenase ($\text{DPD}$) that exhibits impaired clearance of fluorouracil, a chemotherapy drug. Patients with this inherited deficiency receiving standard fluorouracil doses face severe drug accumulation, which has resulted in fatal central nervous system injury.

Genetic Variants Altering Normal and Malignant Cellular Drug Targets

Genetic variants can alter the physical structure or expression levels of drug receptors and target molecules, occurring both in normal host cells and in malignant cells or infectious viruses.

In normal host cells, variants in the gene coding for the beta-1 adrenergic receptor ($\text{ADRB1}$) produce receptors that display hyperresponsiveness to agonist activation. In patients with hypertension, agonist stimulation of these variant receptors induces exaggerated blood pressure elevations. Conversely, administration of beta-blockers (such as metoprolol) produces an exaggerated antihypertensive response due to enhanced receptor blockade. Population studies demonstrate that hyperresponsive $\text{ADRB1}$ variants occur more frequently in individuals of European ancestry than in those of African ancestry, providing an explanation for why beta-blockers display higher average efficacy in light-skinned populations compared to dark-skinned populations. The FDA currently issues no formal testing recommendation for $\text{ADRB1}$.

Warfarin target sensitivity is governed by vitamin K epoxide reductase complex 1 ($\text{VKORC1}$). Warfarin exerts its anticoagulant effect by inhibiting $\text{VKORC1}$, thereby preventing the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle. Single nucleotide polymorphisms (SNPs) in the $\text{VKORC1}$ gene, such as the -1639\text{G}>\text{A} variant, produce an enzyme complex that is highly sensitive to warfarin inhibition. Patients carrying variant $\text{VKORC1}$ alleles require significantly reduced warfarin doses to achieve therapeutic anticoagulation; standard dosing results in excessive anticoagulation and hemorrhage. Variant alleles of $\text{VKORC1}$ and $\text{CYP2C9}$ collectively account for the largest proportion of known variability in warfarin dosage requirements. The FDA recommends genetic testing for $\text{VKORC1}$ variants prior to initiating warfarin therapy.

In malignant cells and viruses, targeted biologic therapies depend on specific biomarker expression:

1. Human epidermal growth factor receptor type 2 ($\text{HER2}$) overexpression: $\text{HER2}$ protein is overexpressed in approximately $25\%$ of breast cancer patients. While $\text{HER2}$ overexpression correlates with an aggressive tumor phenotype and poor prognosis, it also predicts a robust therapeutic response to trastuzumab (Herceptin), a targeted monoclonal antibody that binds $\text{HER2}$ receptors. The FDA requires confirmed positive test results for $\text{HER2}$ overexpression before trastuzumab therapy can be administered.

2. Epidermal growth factor receptor ($\text{EGFR}$) expression: Cetuximab (Erbitux) is indicated primarily for metastatic colorectal cancer and functions exclusively against tumors that express $\text{EGFR}$. Tumors lacking $\text{EGFR}$ expression are completely unresponsive to cetuximab. The FDA mandates verified documentation of $\text{EGFR}$ expression prior to drug initiation.

3. Chemokine receptor 5 ($\text{CCR5}$) tropism: Maraviroc (Selzentry) is an antiretroviral drug for HIV infection that binds to the viral host surface protein chemokine receptor 5 ($\text{CCR5}$), blocking viral entry into immune cells. Maraviroc is effective only against HIV strains that selectively utilize $\text{CCR5}$ for entry, designated as $\text{CCR5}$-tropic strains. The FDA requires pre-treatment tropism testing to confirm that the patient's HIV strain is $\text{CCR5}$-tropic before maraviroc administration.

Genetic Variants Altering Immune Responses and Hypersensitivity

Genetic variations in human leukocyte antigen ($\text{HLA}$) genes alter immune system recognition, predisposing individuals to severe, life-threatening drug hypersensitivity reactions.

Carbamazepine (Tegretol), an anticonvulsant and mood stabilizer used in epilepsy and bipolar disorder, can induce severe cutaneous adverse reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. This toxicity is strongly associated with the $\text{HLA-B*1502}$ allele, which is overwhelmingly present in individuals of Asian ancestry. The interaction between $\text{HLA-B*1502}$ molecules and carbamazepine or its metabolites triggers a cytotoxic cell-mediated immune response. The FDA recommends screening all patients of Asian descent for the $\text{HLA-B*1502}$ gene prior to initiating carbamazepine; if the test is positive, carbamazepine must be avoided.

Abacavir (Ziagen), a nucleoside reverse transcriptase inhibitor used for HIV infection, can trigger severe, potentially fatal systemic hypersensitivity reactions in patients carrying the $\text{HLA-B*5701}$ allele. The FDA recommends genetic screening for $\text{HLA-B*5701}$ prior to abacavir administration. If the $\text{HLA-B*5701}$ allele is detected, abacavir therapy is strictly contraindicated.

Clinical Pharmacogenomic Testing Modalities and Direct-to-Consumer Kits

To perform comprehensive pharmacogenomic testing, clinical providers must utilize accredited diagnostic facilities capable of accurate biomarker analysis. Diagnostic specimens may include blood, saliva, urine, amniotic fluid, tissue biopsies, or hair, depending on the specific test protocol. Driven by expanding technological innovation and research investments, there are over $70{,}000$ genetic testing products available on the United States market, with approximately $10$ new testing products entering the market daily. Multiplexing test panels now allow clinicians to evaluate multiple genetic biomarkers simultaneously from a single patient sample.

Public accessibility to genetic testing has expanded significantly. In $2018$, the FDA granted approval for the first direct-to-consumer (DTC) genetic test kit for assessing breast cancer risk, marketed by 23andMe. Utilizing a consumer-provided saliva sample, this kit tests for $3$ specific founder mutations within the $\text{BRCA1}$ and $\text{BRCA2}$ genes. However, the FDA cautions patients and healthcare providers against using this DTC test as a definitive guide for clinical treatment decisions. The primary limitation is that over $1000$ distinct mutations exist across the $\text{BRCA1}$ and $\text{BRCA2}$ genes, whereas the DTC panel screens exclusively for $3$ founder variants.

Shortly after approving the 23andMe BRCA test kit, the FDA granted further authorization for the 23andMe Personal Genome Service Pharmacogenetic Report. This direct-to-consumer product provides consumers with information regarding specific genetic variants that alter drug metabolism pathways.

Implementation Barriers: Education, Financial Costs, and Logistics

Despite the potential of pharmacogenomics, several substantive barriers impede its widespread integration into clinical practice. A primary obstacle is the widespread lack of education among healthcare providers. Because pharmacogenomics is a rapidly evolving discipline, many clinicians lack the formal training and confidence required to select, order, and interpret genetic tests, or to provide informed patient counseling. Although specialized online educational resources exist, formal pharmacogenomic curriculum requirements remain insufficient across graduate health professional programs.

Financial cost and variable insurance coverage constitute another major barrier. Many commercial health insurance plans do not classify genetic testing as a routine preventive service. While increasing numbers of insurers cover full or partial testing costs when explicitly recommended by a healthcare provider, out-of-pocket costs for genetic testing remain variable, ranging from \n\$100 to \n\$2000 depending on the complexity of the test or multi-gene panel.

Logistical delays also complicate acute care management. Patients must be informed during pre-test counseling that turnaround times for complex laboratory genetic analyses often extend to weeks or longer, which may delay drug therapy initiation.

Ethical, Legal, and Confidentiality Implications of Genetic Testing

Prior to genetic evaluation, clinicians must obtain formal informed consent. Providers are required to educate patients regarding the explicit rationale for testing, potential diagnostic results, treatment modifications based on findings, and expected turnaround times. Genetic test results constitute sensitive protected health information and must maintain strict confidentiality.

Fear of genetic discrimination by employers, insurance underwriters, or healthcare entities represents a documented patient concern. To address these vulnerabilities, the United States Congress enacted the Genetic Information Nondiscrimination Act (GINA) in $2008$. GINA establishes federal legal protections prohibiting employers and health insurance companies from discriminating against individuals based on their genetic information or test results.

However, critical statutory exceptions exist under GINA. Federal protections under GINA do not extend to active-duty military personnel receiving care through the armed forces, veterans receiving care through the Veterans Administration (VA), individuals receiving services through the Indian Health Service, or applicants seeking life insurance, disability insurance, or long-term care insurance policies.

Clinical Implementation Guidelines and Professional Society Positions

Because pharmacogenomics remains a relatively new clinical discipline, comprehensive practice guidelines are still developing. The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides the largest body of evidence-based clinical guidelines. As of $2022$, CPIC has published $26$ detailed practice guidelines covering individual drugs, including codeine, warfarin, clopidogrel, and allopurinol. Each CPIC guideline outlines commonly tested gene variants, details their functional impact on drug response, and offers concrete therapeutic recommendations based on patient genotypes.

International guideline initiatives include the Royal Dutch Association for the Advancement of Pharmacy Pharmacogenetics Working Group (DPWG) and the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). Both organizations publish clinical recommendations for adjusting drug therapy according to genetic variations. These international guidelines are compiled and accessible via the Pharmacogenomics Knowledgebase (PharmGKB) platform.

Medical specialty societies continue to evaluate the clinical readiness of pharmacogenomic testing:

• The American Psychiatric Association (APA) Task Force for Novel Biomarkers and Treatments stated in $2018$ that current clinical evidence remains insufficient to establish definitive practice guidelines for psychiatric pharmacogenomic testing.

• The National Comprehensive Cancer Network (NCCN) regularly publishes clinical practice guidelines mandating targeted oncological therapies based on tumor genetic variants.

• The American Society of Nephrology (ASN) published Clinical Pharmacogenomics: Applications in Nephrology in October $2018$, providing a clinical guidance summary for pharmacogenomic application among commonly prescribed renal medications.

In the future, routine clinical pharmacogenomic profiling may enable fully individualized precision medicine tailored to every patient's genotype. Currently, despite rapid expansion in genomic knowledge, pharmacogenomic science remains an emerging field requiring continued clinical validation.